Конструирование и изучение рекомбинантных аденовирусов CELO в экспериментах in vitro и in vivo

1. Грин М. Трансформация и онкогенез, ДНК-содержащие вирусы. // «Вирусология» ред. Филдс, «Мир», 1989.

2. Женодарова С. М. Синтетические эндорибонуклеазы. // Молекулярная биология, 1993, v.- 27 (2),. pp.- 245−268.

3. Кругляк В. А., Акопиан Т. А., Народицкий Б. С., Карташова И. М., Шевлягин В. Я., Тихоненко Т. И. // Молекулярная генетика, микробиология и вирусология., 1988, v.- 5, pp.- 27−30.

4. Маниатис Т., Фрич Э., Сэмбрук Дж. Молекулярное клонирование.// М., «Мир», 1982.

5. Сюрин В. Н., Самуйленко А. Я., Соловьев Б. В., Фомина Н. В. // Вирусные болезни животных. М.: ВНИТИБП, 1998. 928с.

6. Хорвиц М. С. Аденовирусы и их репликация. // «Вирусология» ред. Филдс, «Мир», 1989.

7. Amado, R.G. et al. A phase I trial of autologous CD3D. hematopoietic progenitor cells transduced with an anti-HIV ribozyme. // Hum. Gene Ther., 1999, v.- 10, pp.-2255−2270.

8. Amalfitano A, Hauser MA, Ни H, Serra D, Begy CR, Chamberlain JS. Production and characterization of improved adenovirus vectors with the El, E2b, and E3 genes deleted. // J. Virol., 1998, v.- 72(2), pp.- 926−933.

9. Batshaw ML, Wilson JM, Raper S, Yudkoff M, Robinson MB. Recombinant adenovirus gene transfer in adults with partial ornithine transcarbamylase deficiency (OTCD). // Hum. Gene Ther., 1999, v.- 10(14), pp.- 24 192 437 .

10. Baxi MK, Deregt D, Robertson J, Babiuk LA, Schlapp T, Tikoo SK. Recombinant bovine adenovirus type 392expressing bovine viral diarrhea virus glycoprotein E2 induces an immune response in cotton rats. // Virology, 2000, v.- 278(1), pp.- 234−243.

11. Benihoud K, Yeh P, Perricaudet M. Adenovirus vectors for gene delivery. // Curr Opin Biotechnol, 1999, v.- 10(5), pp.- 440−447.

12. Bergelson JM, Cunningham JA, Droguett G, KurtJones EA, Krithivas A, Hong JS, Horwitz MS, Crowell RL, Finberg RW. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. // Science, 1997, v.-275(5304), pp.- 1320−1323.

13. Bergelson JM, Krithivas A, Celi L, Droguett G, Horwitz MS, Wickham T, Crowell RL, Finberg RW. The murine CAR homolog is a receptor for coxsackie B viruses and adenoviruses. // J. Virol., 1998, v.- 72(1), pp.- 415−419.

14. Berkner KL. Development of adenovirus vectors for the expression of heterologous genes. // Biotechniques, 1988, v.- 6(7), pp.- 616−629.

15. Bruder JT, Jie T, McVey DL, Kovesdi I. Expression of gpl9K increases the persistence of transgene expression from an adenovirus vector in the mouse lung and liver. // J. Virol., 1997, v.- 71(10), pp.- 7623−7628.

16. Burgert H.S., Kvist S. An adenovirus type 2 glycoprotein blok cell surface expression of human histocompatibility class 1 antigenes. // Cell, 1985, v.-41, p.- 987.93.

17. Burgert H.S., Kvist S. The E3−19K protein of adenovirus type 2 binds to the domain of histocompatibility antigenes required for CTL recognition. // EMBO J., 1987, v.- 6, p.- 2019.

18. Cantor G.H., McElwain T.F., Birkebak T.A., Palmer G.H. Ribozyme cleaves rex/tax mRNA and inhibits bovine leukemia virus expression. // Proc. Natl. Acad. Sci. USA, 1993, v.- 90, pp.- 10 932−10 936.

19. Cech TR, Zaug AJ, Grabowski PJ. In vitro splicing of the ribosomal RNA precursor of Tetrahymena: involvement of a guanosine nucleotide in the excision of the intervening sequence. // Cell, 1981, v.- 27(3 Pt 2), pp.- 487−496.

20. Chen HH, Mack LM, Kelly R, Ontell M, Kochanek S, Clemens PR. Persistence in muscle of an adenoviral vector that lacks all viral genes. // Proc. Natl. Acad. Sci. U S A, 1997, v.- 94(5), pp.- 1645−1650.

21. Cheshenko N, Krougliak N, Eisensmith RC, Krougliak VA. A novel system for the production of fully deleted adenovirus vectors that does not require helper adenovirus. // Gene Ther., 2001, v.- 8(11), pp.- 846−854.

22. Chillon M., Kremer E.J. Trafficking and propagation of canine adenovirus vectors lacking a known integrin-interacting motif. // Hum. Gene Ther., 2001, v.-12(14), pp.-1815−1823.

23. Chinnadurai G., Chinnadurai S., Brusca J. Physical mapping of a large-plaque mutation of adenovirus type 2. // J. Virol. 1979. v.-32, pp.- 623−629.

24. Chiocca, S., A. Baker, and M. Cotten. Identification of a novel antiapoptotic protein, GAM-1, encoded by the CELO adenovirus. // J. Virol., 1997, v.-71, pp.- 3168−3177.94.

25. Chiocca S., Kurzbauer R., Schaffner J., Baker A., Maunter V., Cotten M. The complete DNA sequence and genomic organization of the avian adenovirus CELO. // J. Virol., 1996, v.- 70, pp.- 2939−2949.

26. Chirmule N, Hughes JV, Gao GP, Raper SE, Wilson JM. Role of E4 in eliciting CD4 T-cell and B-cell responses to adenovirus vectors delivered to murine and nonhuman primate lungs. // J. Virol., 1998, v.- 72(7), pp.- 6138−6145.

27. Chomczynski P. A reagent for the single-step simultaneous isolation of RNA, DNA and protein from cell and tissue samples. // BioTechniques, 1993, v.- 15, pp.~ 532−537.

28. Christoffersen R.E., Marr J.J. Ribozymes as human therapeutic agents. // J. of Med. Chemistry, 1995, v.- 38, pp.- 2023;2037.

29. Clemens PR, Kochanek S, Sunada Y, Chan S, Chen HH, Campbell KP, Caskey CT. In vivo muscle gene transfer of full-length dystrophin with an adenoviral vector that lacks all viral genes. //.Gene Ther., 1996, v.- 3(11, pp.-965−972.

30. Cotten M, Wagner E, Zatloukal K, Birnstiel ML. Chicken adenovirus (CELO virus) particles augment receptor-mediated DNA delivery to mammalian cells and yield exceptional levels of stable transformants. // J. Virol., 1993, v.- 67(7), pp.-3777−3785.

31. Cowen B, Calnek BW, Menendez NA, Ball RF. Avian adenoviruses: effect on egg production, shell quality, and feed consumption. // Avian Dis., 1978, v.- 22(3), pp.-459−470.95.

32. Curiel DT. High-efficiency gene transfer employing adenovirus-polylysine-DNA complexes. // Nat. Immun., 1994, v.- 13(2−3), pp.- 141−164.

33. Curiel DT, Agarwal S, Wagner E, Cotten M. Adenovirus enhancement of transferrin-polylysine-mediated gene delivery. // Proc. Natl. Acad. Sci. USA, 1991, v.-88 (19), pp.- 8850−8854.

34. Dahm S.C., Uhlenbeck O.C. Role of divalent metal ions in the hammerhead RNA cleavage reaction. // Biochem., 1991, v.- 30, pp.- 9464−9469.

35. Douglas JT, Miller CR, Kim M, Dmitriev I, Mikheeva G, Krasnykh V, Curiel DT. A system for the propagation of adenoviral vectors with genetically modified receptor specificities. // Nat. Biotechnol., 1999, v.- 17(5), pp.- 470−475.

36. Einfeld DA, Brough DE, Roelvink PW, Kovesdi I, Wickham TJ. Construction of a pseudoreceptor that mediates transduction by adenoviruses expressing a ligand in fiber or penton base. // J. Virol., 1999, v.- 73(11), pp.- 91 309 136.96.

37. Feng M., Cabrera G., Deshane J., Scanlon K.J., Curiel D.T. Neoplastic reversion accomplished by high efficiency adenoviral-mediated delivery of an anti-ras ribozyme. // Cancer Res., 1995, v.- 55, pp.- 2024;2028.

38. Feng M., Jackson W.H., Goldman C.K., Rancourt C., Wang M., Dusing S.K., Siegal G., Curiel D.T. Stable in vivo transduction via a novel adenoviral/retroviral chimeric vector. // Nature Biotech., 1997, v.- 15, pp.-866−870.K.

39. Ferrari F.K., Samulski T., Shenk T., Samulski R.J. Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. // J.Virol., 1996, v.-70, pp.- 3227−3234.

40. Forster A.C. and Symons R.H. Self-cleavage of plus and minus RNAs of a virusoid and a structural model for the active sites. // Cell, 1987, v.- 49, pp.- 211−220.

41. Francois A., Eterradossi N., Delmas B., Payet V., Langlois P. Construction of avian adenovirus CELO recombinants in cosmids. // J. Virol., 2001, v.- 75, pp.~ 5288−5301.

42. Gabathuler R., Levy F., Kvist S. Requirements for the assosiation of adenovirus type 2 E3/19K wild-type and mutant proteins with HLA antigens. // J. Virol., 1990, v.- 64(8), pp. -3679−3685.97.

43. Gall J, Kass-Eisler A, Leinwand L, Falck-Pedersen E. Adenovirus type 5 and 7 capsid chimera: fiber replacement alters receptor tropism without affecting primary immune neutralization epitopes. // J. Virol., 1996, v.- 70(4), pp.- 2116−2123.

44. Gao GP, Yang Y, Wilson JM. Biology of adenovirus vectors with El and E4 deletions for liver-directed gene therapy. // J. Virol., 1996, v.- 70(12), pp.- 8934−8943.

45. Gaughan DJ, Whitehead AS. Function and biological applications of catalytic nucleic acids. // Biochim. Biophys. Acta., 1999, v.- 1445(1), pp.- 1−20.

46. Ghosh-Chounhury G., Haj-Ahmad Y., Brikley P., Rudy J., Graham F.L. Human adenovirus cloning vector based on infectious bacterial plasmids. // Gene, 1986, v.- 50, pp.- 161−171.

47. Ghosh-Choundhury G., Haj-Ahmad Y., Graham F.L. Protein IX, a minor component of the human adenovirus capsid is essential for the packaging of full-lenght genome. // EMBO J., 1987, v.- 6, p.- 1733.

48. Ginsberg H.S. Role of early region 3 (E3) in pathogenesis of adenovirus disease. // Proc.Natl.Acad.Sci.USA., 1989, v.- 86, p.-3823.

49. Glotzer JB, Saltik M, Chiocca S, Michou AI, Moseley P, Cotten M. Activation of heat-shock response by an adenovirus is essential for virus replication. // Nature, 2000, v.- 407(6801), pp.- 207−211.98.

50. Graham F.L. Transformation by and oncogenicity of human adenoviruses. // The Adenoviruses, ed.H.S.Ginsberg, 1984.

51. Graham F.L. and van der Eb A., J. A new technique for the assay of infectivity of human adenovirus 5 DNA.// Virology, 1973, v.- 52, pp.- 456−467.

52. Graham F.L. and Prevec L. Manipulation of adenovirus vectors. // Methods in Mol.Biol., 1994, v.-7, pp.-109−127. (Ed.), The Humana Press Inc., Clifton, NJ.

53. Graham FL, Smiley J, Russell WC, Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. // J. Gen. Virol., 1977, v.-36(1), pp.- 59−74.

54. Green K.Y., Wold W.S.M. Human adenoviruses: growth, purification and transfection assay.// Methods Enzymology, 1980, v.-80, pp.- 425−431.

55. Grunhaus A., Horwitz M. Adenoviruses as cloning vectors. // Semin virol., 1992; v.- 3, pp.- 237−252.

56. Habib NA, Hodgson HJ, Lemoine N, Pignatelli M. A phase I/II study of hepatic artery infusion with wtp53-CMV-Ad in metastatic malignant liver tumours. // Hum. Gene Ther., 1999, v.- 10(12), pp.- 2019;2034.

57. Hampel A. The hairpin ribozyme: discovery, two-dimensional model, and development for gene therapy. // Prog, in Nucleic Acid Res. and Mol. Biol., 1998, v.- 58, pp.- 1−39.

58. Hanahan D. Studies of transformation of Escherichia coli with plasmids. // Journal of Molecular Biology, 1983, v.166, pp.- 557−580.

59. Hannania E.G., Kavanagh J., Hortobagyi G., Gilles R.E., Champlin R., Deisseroth, A.B. Recent advances in the application of gene therapy to human disease. // Am. J. Med, 1995, v.- 99, pp.- 537−552.

60. Hemstrom C., Nordvist K., Petterson U., Virtanen A. Gene products of region E4 of adenovirus type 5 modulates accumulation of certain viral polipeptides. // J. Virol., 1988, v.- 62, pp. -3258−3264.

61. Herman JR, Adler HL, Aguilar-Cordova E, Rojas-Martinez A, Woo S, Timme TL, Wheeler TM, Thompson TC, 100.

62. Scardino PT. In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial. // Hum. Gene Ther., 1999, v.- 10(7), pp.- 1239−1249.

63. Hess M., Cuzange A., Ruigrok R.W.H., Chroboczek J., Jacrot B. The avian adenovirus penton: two fibres and one base. // J. Mol. Biol., 1995, v.- 252, pp.- 379−385.

64. Hillerman M.R., Werner J.H. Recovery of new agents from patientes with acute respiratory illness. // Proc. Soc. Exp. Biol. Med., 1954, v.- 85, pp.- 183−188.

65. Hillgenberg M, Schnieders F, Loser P, Strauss M. System for efficient helper-dependent minimal adenovirus construction and rescue. // Hum. Gene Ther., 2001, v.-12 (6), pp.- 643−657.

66. Holmes D., Quigley M. A rapid boiling method for the preparation of bacterial plasmids. // Anal. Biochem., 1981, v.-114, p.- 193.

67. Hu H, Serra D, Amalfitano A. Persistence of an El-, polymerase-. adenovirus vector despite transduction of a neoantigen into immune-competent mice. // Hum. Gene Ther., 1999, v.- 10(3), pp.- 355−364.

68. Huang S., Stupack D., Mathias P., Wang Y., Nemerow G. Growth arrest of Epstein-Barr virus immortalized B lymphocytes by adenovirus-delivered ribozymes. // Proc. Natl. Acad. Sei. USA, 1997, v.- 94, pp.- 8156−8161.

69. Irie, A. et al. Therapeutic efficacy of an adenovirus-mediated anti-H-ras ribozyme in experimental bladder cancer. // Antisense Nucleic Acid Drug Dev., 1999, v.- 9, pp.- 341−349.

70. Johnson MA, Pooley C, Lowenthal JW. Delivery of avian cytokines by adenovirus vectors. // Dev. Comp. Immunol., 2000, v.- 24(2−3), pp.-343−354.

71. Kaplan JM, Armentano D, Scaria A, Woodworth LA, Pennington SE, Wadsworth SC, Smith AE, Gregory RJ. Novel role for E4 region genes in protection of adenovirus vectors from lysis by cytotoxic T lymphocytes. // J. Virol., 1999, v.- 73(5), pp.- 4489−4492.

72. Karlsson S, Van Doren K, Schweiger SG, Nienhuis AW, Gluzman Y. Stable gene transfer and tissue-specific expression of a human globin gene using adenoviral vectors. // EMBO J., 1986, v.- 5(9), pp.- 2377−2385.

73. Kawaguchi T, Nomura K, Hirayama Y, Kitagawa T. Establishment and characterization of a chicken hepatocellular carcinoma cell line, LMH. // Cancer Res., 1987, v.- 47(16), pp.- 4460−4464.

74. Kelly T.J. Adenovirus DNA replication. // The Adenoviruses, ed. by H.S.Ginsberg, 1984.

75. Kelly T.J., Lewis, A.M. Use of nondefective adenovirus-simian virus 40 hybrids for mapping the SV40 genome. // J. Virol., 1973, v.- 12, pp.- 643−652.

76. Ketner G., Bridge E., Virtanen A., Hemstrom C., Petterson U. Complimentation of adenovirus E4 mutants by102transient expression of E4 cDNA and deletion plasmids. // Nuclear Acids Research, 1989, v.- 17, p.- 3037.

77. Kim IH, Jozkowicz A, Piedra PA, Oka K, Chan L Lifetime correction of genetic deficiency in mice with a single injection of helper-dependent adenoviral vector. // Proc. Natl. Acad. Sci. USA, 2001, v.- 98(23), pp.-13 282−13 287.

78. Klessig D.F. Adenovirus-SV-40 interactions. // The Adenoviruses, ed. H.S.Ginsberg, 1984.

79. Koizumi M., Iwai Sh., Ohtsuka E. Design of RNA enzymes distinguishing a single base mutation in RNA. // Nucleic Acids Res, 1989, v.- 17, pp.- 7059−7071.

80. Korner H., H.G. Burgert Down-Regulation of HLA Antigens by the Adenovirus Type 2 E3/19K Protein in a T1031. mphoma Cell Line // J. Virol., 1994, v.- 68, pp.- 14 421 448.

81. Kovesdi I, Brough DE, Bruder JT, Wickham TJ. Adenoviral vectors for gene transfer. // Curr Opin Biotechnol., 1997, v.- 8(5), pp.- 583−589.

82. Krasnykh VN, Mikheeva GV, Douglas JT, Curiel DT. Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism. // J. Virol., 1996, v.-70 (10), pp.- 6839−6846.

83. Kremer E.J., Boutin S., Chillon M., Danos 0. Canine adenovirus vectors: an alternative for adenovirus-mediated gene transfer. // J. Virol., 2000, v.- 74(1), pp.- 505−512.

84. Krug R.N., Alonso-Caplan F.V., Julkunen I., Katz, M.G. Expression and replication of the influenza virus genome. // In: Krug, R.M. (ed). The influenza Viruses, pp.89−152, Plenum Press, New York, 1989.

85. Laver WG, Younghusband HB, Wrigley NG. Purification and properties of chick embryo lethal orphan virus (an avian adenovirus). // Virology, 1971, v.- 45(3), pp.- 598−614.

86. Lehrmann, H., and M. Cotten. Characterization of CELO virus proteins that modulate the pRb/E2 °F pathway. // J. Virol., 1999, v.- 73, pp.- 6517−6525.

87. Li M., Lonial H., Citarella R., Lindh D., Colina L., Kramer R. Tumor inhibitory activity of anti-ras ribozymes delivered by retroviral gene transfer. // Cancer Gene. Ther., 1996, v.- 3, pp.- 221−229.

88. Li P., Bellett A.J.D., Parish C.R. The structural proteins of chick embryo lethal orphan virus (fowl adenovirus type 1). // J. Gen. Virol., 1984, v.- 65, pp.- 1803−1815.

89. Li, X. et al. Gene therapy targeting cord blood-derived CD34(+) cells from HIV-exposed infants: preclinical studies. // Gene Ther., 1998, v.- 5, pp.- 233 239.

90. Lieber, A. et al. Elimination of hepatitis C virus RNA in infected human hepatocytes by adenovirus-mediated expression of ribozymes. // J. Virol., 1996, v.-70, pp.-8782−8791.

91. Lieber A, He CY, Polyak SJ, Gretch DR, Barr D, Kay MA. Elimination of hepatitis C virus RNA in infected human hepatocytes by adenovirus-mediated expression of ribozymes. ///J. Virol., 1996, v.- 70(12), pp.- 8782−8791.

92. Lieber A., Kay M.A. Adenovirus-mediated expression of ribozymes in mice. // J. Virol., 1996, v.-70, pp.- 3153−3158.

93. Lieber A, Steinwaerder DS, Carlson CA, Kay MA. Integrating adenovirus-adeno-associated virus hybrid vectors devoid of all viral genes. // J. Virol., 1999, v.-73(11), pp.- 9314−9324.105.

94. Legerski R., Robberson D. Analysis and optimization of recombinant DNA joining reactions. // Journal of Molecular Biology, 1985, v.- 181, pp.- 297−312.

95. Looney, D. and Yu, M. Clinical aspects of ribozymes as therapeutics in gene therapy. // Methods Mol. Biol., 1997, v.- 74, pp.- 469−486.

96. Mahy B.W.J. (Ed.). Virology. A practical approach, 1988, IRL Press, Oxford-Washington DC.

97. Mathias P, Wickham T, Moore M, Nemerow G. Multiple adenovirus serotypes use alpha v integrins for infection. // J. Virol., 1994, v.- 68(10), pp.- 6811−6814.

98. Mayr GA, O’Donnell V, Chinsangaram J, Mason PW, Grubman MJ. Immune responses and protection against foot-and-mouth disease virus (FMDV) challenge in swine vaccinated with adenovirus-FMDV constructs. // Vaccine, 2001, v.- 19(15−16), pp.- 2152−2162.

99. Michael SI, Hong JS, Curiel DT, Engler JA. Addition of a short peptide ligand to the adenovirus fiber protein. // Gene Ther., 1995, v.- 2(9), pp.- 660−668.106.

100. Michou A., Lehrmann H., Saltik M., Cotten M. Mutational analysis of the avian adenovirus CELO, which provides a basis for gene delivery vectors. // J. Virol., 1999, v.- 73, pp.- 1399−1410.

101. Mitrasinovic 0. and Epstein L.M. Differences in the phosphate oxygen requirements for self-cleavage by the extended and prototypical hammerhead forms. // Nucleic Acids Res, 1997, v.- 25, pp.- 2189−2196.

102. Miyazawa N, Leopold PL, Hackett NR, Ferris B, Worgall S, Falck-Pedersen E, Crystal RG. Fiber swap between adenovirus subgroups B and C alters intracellular trafficking of adenovirus gene transfer vectors. // J. Virol., 1999, v.- 73(7), pp.- 6056−6065.

103. Moore M, Horikoshi N, Shenk T Oncogenic potential of the adenovirus E4orf6 protein // Proc. Natl. Acad. Sci. USA, 1996, v.- 93(21), pp.- 11 295−11 301.

104. Moorhead JW, Clayton GH, Smith RL, Schaack J. A replication-incompetent adenovirus vector with the preterminal protein gene deleted efficiently transduces mouse ears. //J. Virol., 1999, v.- 73(2), pp.- 1046−1053.

105. Muotri A.R., da Veiga Pereira L., dos Reis Vasques L., Menck CF. Ribozymes and the anti-gene therapy: how a catalytic RNA can be used to inhibit gene function. // Gene, 1999, v.- 237(2), pp.-303−310.

106. Nemerow GR, Stewart PL. Role of alpha (v) integrins in adenovirus cell entry and gene delivery. // Microbiol. Mol. Biol. Rev., 1999, v.- 63(3), pp.- 725−734.

107. Nermut M.V. The architecture of adenoviruses. // The Adenoviruses, ed. By H.S. Ginsberg, 1984.

108. Nishikawa Y., Iwata A., Katsumata A., Xuan X., Nagasawa H., Igarashi I., Fujisaki K., Onsuka H., Mikami T. Expression of canine interferon-gamma by a recombinant vaccinia virus and its antiviral effect. // Virus Res., 2001, v.- 75(2), pp.- 113−121.

109. Nyberg-Hoffman C, Aguilar-Cordova E. Instability of adenoviral vectors during transport and its implication for clinical studies. // Nat. Med., 1999, v.- 5(8), pp.-955−957.

110. Ojwang, J.O. et al. Inhibition of human immunodeficiency virus type 1 expression by a hairpin ribozyme. Proc. Natl. Acad. Sci. U. S. A., 1992, v.-89, pp.- 10 802−10 806.

111. Okuda Y, Ono M, Yazawa S, Imai Y, Shibata I, Sato S. Pathogenicity of serotype 1 fowl adenovirus in commercial broiler chickens. // Avian Dis., 2001, v.-45(4), pp.- 819−827.

112. Okuda Y, Ono M, Yazawa S, Shibata I, Sato S. Experimental infection of specific-pathogen-free chickens with serotype-1 fowl adenovirus isolated from a broiler chicken with gizzard erosions. // Avian Dis., 2001, v.-45 (1), pp.- 19−25.108.

113. Ono M, Okuda Y, Yazawa S, Shibata I, Tanimura N, Kimura K, Haritani M, Mase M, Sato S Epizootic outbreaks of gizzard erosion associated with adenovirus infection in chickens. // Avian Dis., 2001, v.- 45(1), pp.- 268−275.

114. Palese P., Kingsbury D.W. Genetic of influenza viruses, published by Springer-Verlag, Wien/New York, 1983.

115. Payet, V., C. Arnauld, J. P. Picault, A. Jestin, and P. Langlois. Transcriptional organization of the avian adenovirus CELO. // J. Virol., 1998, v.- 72, pp.- 92 789 285.

116. Pyle A.M. Ribozymes: a distinct class of metalloenzymes. // Science, 1993, v.- 261, pp.- 709−714.

117. Rasmussen U.B., Benchaibi M., Meyer V., Schlesinger Y., Schughart K. Novel human gene transfer vectors: evaluation of wild-type and recombinant animal adenoviruses in human-derived cells. // Hum. Gene Ther., 1999, v.- 10(16), pp.- 2587−2599.

118. Reddy PS, Idamakanti N, Babiuk LA, Mehtali M, Tikoo SK. Porcine adenovirus-3 as a helper-dependent expression vector. // J. Gen. Virol., 1999, v.- 80(11), pp.- 2909−2916.109.

119. Reddy PS, Idamakanti N, Chen Y, Whale T, Babiuk LA, Mehtali M, Tikoo SK. Replication-defective bovine adenovirus type 3 as an expression vector. // J. Virol., 1999, v.- 73(11), pp.- 9137−9144.

120. Reddy PS, Idamakanti N, Hyun BH, Tikoo SK, Babiuk LA. Development of porcine adenovirus-3 as an expression vector. // J. Gen. Virol., 1999, v.- 80(3), pp.- 563−570.

121. Roelvink PW, Mi Lee G, Einfeld DA, Kovesdi I, Wickham TJ. Identification of a conserved receptor-binding site on the fiber proteins of CAR-recognizing adenoviridae. // Science, 1999, v.- 286(5444), pp.- 15 681 571.

122. Romano G., Micheli P., Pacilio C., Giordano A. Latest developments in gene transfer technology: achievements, perspectives, and controversies over therapeutic applications. // Stem Cells, 2000, v.- 18(1), pp.-19−39.

123. Rowe W.P., Huebner R.J., Gilmor L.K., Parrott R.H., Ward T.G. Isolation of a cytopathogenic agent from human adenoids undergoigs spontaneous degeneration in tissue culture. // Proc. Soc. Exp. Biol. Med., 1953, v.-84, pp.- 570−573.

124. Sanger F., Nicklen S., Coulson A. DNA sequencing with chain-terminating inhibitors. // Proc. Natl. Acad. Sei. USA, 1977, v.74, pp.-5463−5467.

125. Sharp P.A. Adenovirus transcription. // The Adenoviruses, ed. H.S.Ginsberg, 1984.

126. Shayakhmetov DM, Lieber A. Dependence of adenovirus infectivity on length of the fiber shaft domain. // J. Virol., 2000, v.- 74(22), pp.- 10 274−10 286.

127. Shayakhmetov DM, Papayannopoulou T, Stamatoyannopoulos G, Lieber A. Efficient gene transfer1. linto human CD34(+) cells by a retargeted adenovirus vector. // J. Virol., 2000, v.- 74(6), pp.- 2567−2583.

128. Shenk T. Adenoviridae: the viruses and their replication. // Fields virology. / Eds Fields B.N., Knipe.

129. D.M., Howley P.M. Fhiladelfhia: 3rd ed. Lippincott-Raven Publishers, 1996, pp.- 2111−2148.

130. Sheppard M, Werner W, Tsatas E, McCoy R, Prowse S, Johnson M. Fowl adenovirus recombinant expressing VP2 of infectious bursal disease virus induces protective immunity against bursal disease. // Arch. Virol., 1998, v.- 143(5), pp.- 915−930.

131. Soudais C., Laplace-Builhe C., Kissa K., Kremer.

132. E.J. Preferential transduction of neurons by canine112adenovirus vectors and their efficient retrograde transport in vivo. // FASEB J., 2001, v.- 15(12), pp.~ 2283−2285.

133. Steitz, T.A. and Steitz, J.A. A general 2-metal-ion mechanism for catalytic RNA. // Proc. Natl. Acad. Sci. U. S. A., 1993, v.- 90, pp.- 6498−6502.

134. Stevenson SC, Rollence M, Marshall-Neff J, McClelland A. Selective targeting of human cells by a chimeric adenovirus vector containing a modified fiber protein. // J. Virol., 1997, v.- 71(6), pp.- 4782−4790.

135. Stevenson SC, Rollence M, White B, Weaver L, McClelland A. Human adenovirus serotypes 3 and 5 bind to two different cellular receptors via the fiber head domain. // J. Virol., 1995, v.- 69(5), pp.- 2850−2857.

136. Stratford-Perricaudet LD, Makeh I, Perricaudet M, Briand P. Widespread long-term gene transfer to mouse skeletal muscles and heart. // J. Clin. Invest., 1992, v.-90(2), pp.- 626−630.

137. Straus S.E. Adenovirus infection in humans. // The Adenoviruses, ed. by H.S.Ginsberg, 1984.

138. Sussenbuch J.S. The Structure of the genome. // The Adenoviruses, ed. by H.S.Ginsberg, 1984.

139. Straus S.E. Adenovirus infection in humans. // The Adenoviruses, ed. by H.S.Ginsberg, 1984.

140. Tan P.K., Michou A., Bergelson J.M., Cotten M. Defining CAR as a cellular receptor for the avian adenovirus CELO using a genetic analysis of the two viral fibre proteins. // J. Gen. Virol., 2001, v.- 82, pp.-1465−1472.

141. Tang X.B., Hobom G., Luo D. Ribozyme mediated destruction of influenza A virus in vitro and in vivo. // J. Med. Virology, v.- 42, pp.- 385−395.

142. Tomko RP, Xu R, Philipson L. HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. // Proc. Natl. Acad. Sci. USA, 1997, v.- 94(7), pp.- 3352−3356.

143. Trapnell BC, Gorziglia M. Gene therapy using adenoviral vectors. // Curr Opin Biotechnol., 1994, v.-5(6), pp.- 617−625.

144. Uhlenbeck O.C. A small catalytic oligoribonucleotide. // Nature, 1987, v.- 328, pp.- 596 600 .

145. Van der Eb A. J., van Kesteren J.W., van Bruggen E.F.J. Structural properties of adenovirus DNAs. // Biochem. Biophys. Acta, 1969, v.- 182, pp.- 530−541.

146. Van der Eb A.J., Mulder C., Graham F.L., Houwelling A. Transformation with specific fragments of adenovirus DNA. I. Isolation of specific fragments with transforming activity of adenovirus 2 and 5 DNA. // Gene, 1977, v.- 2, pp.- 115−132.114.

147. Vile R.G. A marriage of viral vectors. // Nature Biotech., 1997, v.- 15, pp.- 840−841.

148. Wang, L. et al. Preclinical characterization of an anti-tat ribozyme for therapeutic application. // Hum. Gene Ther., 1998, v.- 9, pp.- 1283−1291.

149. Wang Q, Greenburg G, Bunch D, Farson D, Finer MH Persistent transgene expression in mouse liver following in vivo gene transfer with a delta El/delta E4 adenovirus vector. // Gene Ther., 1997, v.- 4(5), pp.- 393−400.

150. Wickham TJ. Targeting adenovirus. // Gene Ther., 2000, v.- 7(2), pp.- 110−114.

151. Wickham TJ, Mathias P, Cheresh DA, Nemerow GR. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. // Cell, 1993, v.- 73(2), pp.- 309−319.

152. Wickham TJ, Segal DM, Roelvink PW, Carrion ME, Lizonova A, Lee GM, Kovesdi I. Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies. // J. Virol., 1996, v.- 70(10), pp.- 6831−6838.

153. Xu ZZ, Both GW. Altered tropism of an ovine adenovirus carrying the fiber protein cell binding domain of human adenovirus type 5. // Virology, 1998, v.- 248(1), pp.- 156−163.

154. Xu ZZ, Hyatt A, Boyle DB, Both GW. Construction of ovine adenovirus recombinants by gene insertion or deletion of related terminal region sequences. // Virology, 1997, v.- 230(1), pp.-62−71.

155. Yates V.J., Fry D.E. Observations on a chicken embryo lethal orphan (CELO) virus. // Am. J. Vet. Res., 1957, v.- 18, pp.- 657−660.115.

156. Zabner J, Chillon M, Grunst T, Moninger TO, Davidson BL, Gregory R, Armentano D. A chimeric type 2 adenovirus vector with a type 17 fiber enhances gene transfer to human airway epithelia. // J. Virol., 1999, v.- 73(10), pp.- 8689−8695.

157. Zabner J, Couture LA, Gregory RJ, Graham SM, Smith AE, Welsh MJ. Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis. // Cell, 1993, v.- 75(2), pp.- 207−216.

158. Zabner J, Freimuth P, Puga A, Fabrega A, Welsh MJ. Lack of high affinity fiber receptor activity explains the resistance of ciliated airway epithelia to adenovirus infection. // J. Clin. Invest., 1997, v.- 100(5), pp.~ 1144−1149.

159. Zhou C., Bahner I., Rossi J.J., Kohn D.B. Expression of hammerhead ribozymes by retroviral vector to inhibit HIV-1 replication: comparison of RNA levels and viral inhibition. // Antisense Nucleic Acid Drug Dev., 1996, v.- 6, pp.- 17−24.

160. Zhou H, Zhao T, Pastore L, Nageh M, Zheng W, Rao XM, Beaudet AL. A Cre-expressing cell line and an El/E2a double-deleted virus for preparation of helper-dependent adenovirus vector. // Mol. Ther., 2001, v.- 3(4), pp.~ 613−622.